The recent regulatory and safety measures regarding the use of Selective Serotonin Reuptake Inhibitors (SSRIs) in children under the age of 18 years proves, yet again, the importance and need for post-marketing pharmacovigilance. This is particularly true for drugs with a potential for off-label use.
With just 72 countries participating as full members in the WHO International Drug Monitoring Programme, it is clear that much work remains to be done in raising awareness about drug safety among Member States. WHO HQ, along with the global experts in public health, is finalizing the document ‘Pharmacovigilance in Public Health’. Once published, it is hoped that this document will demonstrate ways in which pharmacovigilance can be introduced, through public health programmes, into countries with no current facility for drug monitoring.
The previous issue of the newsletter published the reports from two of the working groups at the Twenty-sixth Annual Meeting of National Centres held in New Delhi, December 2003. In this issue we bring you suggestions from the other two working groups, on the subject of improving adverse drug reaction reporting in member countries.